TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03934476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise HIIT
Description: The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise HIIT
Description: The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.
Study: NCT04062955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02466256

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intraocular lens implantation
Description: Intraocular lens implantation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intraocular lens implantation
Description: Intraocular lens implantation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Autosert Injector
Description: Motorised injection device for intraocular lens implantation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Royale Injector
Description: Manual, plunger type injection device for intraocular lens implantation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Monarch III Injector
Description: Manual, screw type injection device for intraocular lens implantation
Study: NCT02795234

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study: NCT01154101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Study: NCT01613872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
Study: NCT03238183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dextrose
Description: compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
Study: NCT01154101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
Study: NCT00215150

Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Sertraline augmentation with ziprasidone

Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
Study: NCT03832088

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Jamar hand dynamometer
Description: Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
Study: NCT03238183

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hyaluronic acid
Description: compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
Study: NCT00263588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: tyrosine kinase inhibitor
Study: NCT01403194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP/BiPAP
Description: Subjects will be treated with either CPAP or Bi-PAP for three months.
Study: NCT04407403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi tailored for lowering blood pressure (PRESSURE)
Description: PRESSURE Tai Chi routine consisted of eight forms following Yang style. PRESSURE was tailored for the targeted health outcome of BP in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored PRESSURE to emphasize slow, deep breathing and relaxation by utilizing Tai Chi movements that: 1) were slow and smooth; 2) without break or pause; and 3) had minimal muscular force and exertion. Investigators included the following eight forms in PRESSURE: 1) Begin Tai Ji Quan; 2) Part the Horse's Mane; 3) Brush Knee and Push; 4) Cloud Hands; 5) Open and Close; 6) Part the Grass; 7) Single Whip; and 8) Finish Tai Ji Quan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi tailored for improving balance (BALANCE)
Description: BALANCE Tai Chi routine consisted of eight forms following Yang style. BALANCE was tailored for the targeted health outcome of balance in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored BALANCE to provide moderate to high levels of challenge to balance control by emphasizing movement principles (e.g., consciously control weight shifting during multi-directional stepping), and integrating Tai Chi movements that: 1) reduced the base of support; 2) moved the center of gravity; and 3) improved lower-extremity strength. Investigators included the following eight forms in BALANCE: 1) Begin Tai Ji Quan; 2) Roll the Ball; 3) Kick with Heel; 4) Repulse the Monkey; 5) Gather the Earth's Qi; 6) White Crane Spread Wing; 7) Fairy Weaves the Shuttle; and 8) Finish Tai Ji Quan.
Study: NCT01931553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized attending morning rounds
Study: NCT01771263

Intervention type: DEVICE
Group type: OTHER
Intervention: iControl-RP
Study: NCT02310386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BEMER electromagnetic field therapy
Description: To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
Study: NCT03832088

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Calf circumference
Description: Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
Study: NCT00971503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow implantation
Description: Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline injection
Description: Injection of saline solution for 5 days
Study: NCT03339453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered nasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Glucagon
Description: Administered IM
Study: NCT03802357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
Study: NCT02480361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture treatment after gastric cancer surgery during 5 postoperative days
Study: NCT03123107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
Study: NCT04503980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: αPD1-MSLN-CAR T cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
Study: NCT02310386

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BEMER electromagnetic field therapy
Description: To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
Study: NCT04413266

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin supplementation
Description: The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin supplementation
Description: The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks
Study: NCT04178590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP + Injectable Platelet-Rich Fibrin
Description: Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP + placebo
Description: Saline application during scaling and root planing
Study: NCT03665597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose C
Description: SC injection
Study: NCT01117220

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
Study: NCT01117220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone Oral Capsules
Description: Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
Study: NCT05394935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Exercise
Description: Acute, low-volume HIIT 12x (1min:1min) Working intensity: \>85% heart rate reserve Resting intensity: Active rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise
Description: Acute, low-volume HIIT 12x (1min:1min) Working intensity: \>85% heart rate reserve Resting intensity: Active rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Exercise
Description: Continuous, MISS 50mins Working intensity: 50-60% heart rate reserve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise
Description: Continuous, MISS 50mins Working intensity: 50-60% heart rate reserve
Study: NCT03992118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent coaching
Description: Parents will be coached to implement behavioural strategies to address factors which are contributing to difficult mealtime behaviours and feeding challenges.
Study: NCT02416271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered SC
Study: NCT02760732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting balloon; cutting balloon
Description: Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting stent
Description: with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.
Study: NCT01859858

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Study: NCT01859858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT06462066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental medical device
Description: Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Gluban Tiss® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator medical device
Description: Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Glubran® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
Study: NCT00858754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylnaltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02691130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric 001 (M-001)
Description: Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric 001 (M-001)
Description: Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Description: Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Description: Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H5N1 influenza vaccine
Description: Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% NaCl in double distilled water
Study: NCT04490005

Intervention type: OTHER
Intervention: pupillometry
Description: evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
Study: NCT05669781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Gum and metoclopramide
Description: Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and one stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum
Description: One stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
Study: NCT04376203

Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Typical Thyroidectomy

Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Typical Thyroidectomy
Study: NCT01468272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: free comb. beclomethasone DPI and formoterol DPI
Description: free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 50/6 NEXT DPI
Description: four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
Study: NCT01071811

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Pedometer-based intervention
Description: The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention
Description: The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
Study: NCT03665597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose C
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose C
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose C
Description: SC injection
Study: NCT02416271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Administered orally
Study: NCT03665597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose A
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose A
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose A
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose A
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose A
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose A
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose B
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose B
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose B
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose B
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose B
Description: IV infusion
Study: NCT02416271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Oral
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-SC
Description: Administered SC
Study: NCT02112227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PACT-HF Model
Description: PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
Study: NCT00908687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: A/H5N1 Low Dose